Troubling trends: Childhood obesity influences fracture risk and recovery patterns

Melina Khorrami, BS; Ali Rezazadeh Shirazi, BS; Pooya Hosseinzadeh, MD, FAAOS

Obesity is now among the most common chronic conditions of childhood, and its effects extend into the fracture clinic.

GLP-1 RA medications are changing the TJR landscape

Thomas Fleeter, MD, MBA, FAAOS

As rates of obesity have increased, so, too, has demand for total joint replacement (TJR).

New studies link GLP-1 receptor agonist medications to tendon rupture risk and changes in bone metabolism

Jad Lawand, MS; Joseph Abboud, MD

The use of GLP-1 receptor agonist (GLP-1 RA) medications has rapidly increased, with randomized controlled studies reporting reductions in major adverse cardiovascular events and diabetic kidney disease progression.

GLP-1 RAs can influence fracture risk based on different medications and patient populations

Alexandra E. Page, MD, FAAOS

The widespread use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has facilitated large population studies examining associations between these medications and a range of health outcomes, including fracture risk.

GLP-1 RAs may affect outcomes after tibial plateau fixation

Amelia R. Goldstein; Kenneth A. Egol, MD, FAAOS

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly encountered in orthopaedic trauma patients presenting for operative fracture fixation.